Home Cart 0 Sign in  
X

[ CAS No. 29274-23-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 29274-23-5
Chemical Structure| 29274-23-5
Chemical Structure| 29274-23-5
Structure of 29274-23-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 29274-23-5 ]

Related Doc. of [ 29274-23-5 ]

Alternatived Products of [ 29274-23-5 ]

Product Details of [ 29274-23-5 ]

CAS No. :29274-23-5 MDL No. :MFCD09746272
Formula : C6H5N3O Boiling Point : -
Linear Structure Formula :- InChI Key :BUEFDJQUUGMUJO-UHFFFAOYSA-N
M.W : 135.12 Pubchem ID :335418
Synonyms :

Calculated chemistry of [ 29274-23-5 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 35.81
TPSA : 50.16 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.9 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.77
Log Po/w (XLOGP3) : 0.31
Log Po/w (WLOGP) : 0.02
Log Po/w (MLOGP) : 0.44
Log Po/w (SILICOS-IT) : 0.66
Consensus Log Po/w : 0.44

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.54
Solubility : 3.91 mg/ml ; 0.0289 mol/l
Class : Very soluble
Log S (Ali) : -0.93
Solubility : 16.0 mg/ml ; 0.119 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.59
Solubility : 3.49 mg/ml ; 0.0258 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.73

Safety of [ 29274-23-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 29274-23-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 29274-23-5 ]
  • Downstream synthetic route of [ 29274-23-5 ]

[ 29274-23-5 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 29274-23-5 ]
  • [ 58347-49-2 ]
YieldReaction ConditionsOperation in experiment
71% at 90℃; PREPARATION 32
7-Chloropyrazolo[1,5-a]pyrimidine
Pyrazolo[1,5-a]pyrimidin-7(4H)-one (0.50g, 3.70 mmols), phosphorus oxychloride (0.88 mL, 9.62 mmols) and diisopropylethylamine (DIEA, 0.13 mL, 0.74 mmols) were mixed and stirred at 90ºC overnight.
It was poured onto water/ice, extracted with dichloromethane and washed with brine.
It was dried, filtered and concentrated in vacuo.
It was purified by chromatography (Silica gel, Hexane/Ethyl acetate 9:1) to afford the expected compound (83 mg, 71percent).
LRMS (m/z): 154 (M+1)+
1H NMR (400 MHz, DMSO-d6) d ppm 6.93 (d, 1 H) 7.43 (d, 1 H) 8.37 (d, 1 H) 8.52 (d, 1 H)
71% at 90℃; Pyrazolo[1 ,5-a]pyrimidin-7(4/-/)-one (0.50g, 3.70 mmols), phosphorus oxychloride (0.88 mL, 9.62 mmols) and diisopropylethylamine (DIEA, 0.13 mL, 0.74 mmols) were mixed and stirred at 90°C overnight. It was poured onto water/ice, extracted with dichloromethane and washed with brine. It was dried, filtered and concentrated in vacuum. It was purified by chromatography (Silica gel, Hexane/Ethyl acetate 9:1 ) to afford the expected compound (83 mg, 71 percent).LRMS (m/z): 154 (M+1 )+ 1H NMR (400 MHz, DMSO-d6) δ ppm 6.93 (d, 1 H) 7.43 (d, 1 H) 8.37 (d, 1 H) 8.52 (d, 1 H)
71% at 90℃; PREPARATION 897-Chloropyrazolo[1 ,5-a]pyrimidinePyrazolo[1 ,5-a]pyrimidin-7(4H)-one (0.50g, 3.70 mmols), phosphorus oxychloride (0.88ml, 9.62 mmols) and diisopropylethylamine (DIEA, 0.13ml, 0.74 mmols) were mixed and stirred at 90°C overnight. It was poured onto water/ice, extracted with dichloromethane and washed with brine. It was dried, filtered and concentrated in vacuum. It was purified by chromatography (Silica gel, Hexane/Ethyl acetate 9:1 ) to afford the expected compound (83mg, 71 percent).LRMS (m/z): 154 (M+1 )+ 1 H N MR (400 MHz, DMSO-d6) d ppm 6.93 (d, 1 H) 7.43 (d, 1 H) 8.37 (d , 1 H) 8.52 (d, 1 H)
65% at 90℃; for 2.5 h; 7-Hydroxypyrazolo[1 ,5-a]pyrimidine (60 g, 444 mmol), phosphorus oxychloride (108 mL, 1.15 mol) and dimethylaniline (10.8 mL, 89 mmol) were added to a 250 mL round- bottomed flask and the contents heated to 90 0C. After 2.5 h, the reaction mixture was allowed to cool and was concentrated. The black residue was poured into a beaker containing crushed ice (600 mL) and the resulting solution kept cold using an ice bath. The aqueous solution was extracted with CH2CI2 (3 χ 150 mL) and the combined organic phase was washed with brine (100 mL). The organic phase was dried and concentrated to yield the desired crude product, 7-chloropyrazolo[1 ,5-a]pyrimidine, (44.2 g, 65percent) as a red solid. As the crude product was sufficiently pure to use in the subsequent step, a small sample was purified by column chromatography (33-66percent EtOAc/hexane) to yield an analytical sample as a white solid. HPLC 95percent; 1H NMR (250 MHz, CDCI3) δ 8.41 (d, J = 4.5 Hz, 1 H), 8.25 (d, J = 2.3 Hz, 1 H)1 6.99 (d, J ~ 4.5 Hz, 1 H), 6.84 (d, J = 2.3 Hz, 1 H); 13C NMR (62.9 MHz, CDCI3) δ 150.0, 148.2, 145.4, 139.0, 108.0, 98.7; MS (APCI) 154 [M+Hf.
47% for 72 h; The compound prepared in preparative example 1 (2.4 g, 17.4 mmol) was stirred in POCl3 (54 mL) and N,N-dimethylaniline (6.7 mL) 3 days. The reaction mixture was concentrated, dissolved in saturated NaHCO3 (2000 mL) and extracted with CH2Cl2, dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography using a 2.5percent MeOH in CH2Cl2 solution as eluent (1.3 g, 47percent yield): M+H=154.

Reference: [1] Patent: EP2518071, 2012, A1, . Location in patent: Page/Page column 38
[2] Patent: WO2012/146667, 2012, A1, . Location in patent: Page/Page column 90
[3] Patent: WO2012/146666, 2012, A1, . Location in patent: Page/Page column 160
[4] Patent: WO2007/17678, 2007, A1, . Location in patent: Page/Page column 44
[5] Journal of Medicinal Chemistry, 1981, vol. 24, # 5, p. 610 - 613
[6] Patent: US2007/82901, 2007, A1, . Location in patent: Page/Page column 21
[7] ChemMedChem, 2014, vol. 9, # 11, p. 2516 - 2527
  • 2
  • [ 29274-23-5 ]
  • [ 877173-84-7 ]
Reference: [1] ChemMedChem, 2014, vol. 9, # 11, p. 2516 - 2527
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 29274-23-5 ]

Amides

Chemical Structure| 77494-09-8

[ 77494-09-8 ]

4-Methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.95

Chemical Structure| 96335-42-1

[ 96335-42-1 ]

5-Aminopyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.92

Chemical Structure| 463327-79-9

[ 463327-79-9 ]

6-Aminopyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.90

Chemical Structure| 29274-35-9

[ 29274-35-9 ]

5-Methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.90

Chemical Structure| 55197-18-7

[ 55197-18-7 ]

4-Ethylpyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.89

Related Parent Nucleus of
[ 29274-23-5 ]

Other Aromatic Heterocycles

Chemical Structure| 77494-09-8

[ 77494-09-8 ]

4-Methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.95

Chemical Structure| 96335-42-1

[ 96335-42-1 ]

5-Aminopyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.92

Chemical Structure| 463327-79-9

[ 463327-79-9 ]

6-Aminopyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.90

Chemical Structure| 29274-35-9

[ 29274-35-9 ]

5-Methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.90

Chemical Structure| 55197-18-7

[ 55197-18-7 ]

4-Ethylpyrazolo[1,5-a]pyrimidin-7(4H)-one

Similarity: 0.89